184 related articles for article (PubMed ID: 36994313)
21. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
22. Insights into product and process related challenges of lentiviral vector bioprocessing.
Perry C; Mujahid N; Takeuchi Y; Rayat ACME
Biotechnol Bioeng; 2023 Aug; ():. PubMed ID: 37526313
[TBL] [Abstract][Full Text] [Related]
23. Bioreactor productivity and media cost comparison for different intensified cell culture processes.
Xu S; Gavin J; Jiang R; Chen H
Biotechnol Prog; 2017 Jul; 33(4):867-878. PubMed ID: 27977910
[TBL] [Abstract][Full Text] [Related]
24. Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch.
Särnlund S; Jiang Y; Chotteau V
Biotechnol Bioeng; 2021 Sep; 118(9):3533-3544. PubMed ID: 33914903
[TBL] [Abstract][Full Text] [Related]
25. Upscaling of lentiviral vector production by tangential flow filtration.
Geraerts M; Michiels M; Baekelandt V; Debyser Z; Gijsbers R
J Gene Med; 2005 Oct; 7(10):1299-310. PubMed ID: 15906396
[TBL] [Abstract][Full Text] [Related]
26. Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.
Hein MD; Chawla A; Cattaneo M; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2021 Oct; 105(19):7251-7264. PubMed ID: 34519855
[TBL] [Abstract][Full Text] [Related]
27. Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.
Gränicher G; Tapia F; Behrendt I; Jordan I; Genzel Y; Reichl U
Biotechnol J; 2021 Jan; 16(1):e2000024. PubMed ID: 32762152
[TBL] [Abstract][Full Text] [Related]
28. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.
Merten OW; Charrier S; Laroudie N; Fauchille S; Dugué C; Jenny C; Audit M; Zanta-Boussif MA; Chautard H; Radrizzani M; Vallanti G; Naldini L; Noguiez-Hellin P; Galy A
Hum Gene Ther; 2011 Mar; 22(3):343-56. PubMed ID: 21043787
[TBL] [Abstract][Full Text] [Related]
29. Continuous production process of retroviral vector for adoptive T- cell therapy.
Inwood S; Xu H; Black MA; Betenbaugh MJ; Feldman S; Shiloach J
Biochem Eng J; 2018 Apr; 132():145-151. PubMed ID: 29977134
[TBL] [Abstract][Full Text] [Related]
30. Large-scale production means for the manufacturing of lentiviral vectors.
Schweizer M; Merten OW
Curr Gene Ther; 2010 Dec; 10(6):474-86. PubMed ID: 21054245
[TBL] [Abstract][Full Text] [Related]
31. Effect of inner diameter, filter length, and pore size on hollow fiber filter fouling during perfusion cell culture.
WuDunn D; Squeri A; Vu J; Dhingra A; Coffman J; Lee K
Biotechnol Prog; 2024 Feb; ():e3440. PubMed ID: 38343012
[TBL] [Abstract][Full Text] [Related]
32. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.
Ansorge S; Lanthier S; Transfiguracion J; Durocher Y; Henry O; Kamen A
J Gene Med; 2009 Oct; 11(10):868-76. PubMed ID: 19618482
[TBL] [Abstract][Full Text] [Related]
33. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification.
Segura MM; Garnier A; Durocher Y; Coelho H; Kamen A
Biotechnol Bioeng; 2007 Nov; 98(4):789-99. PubMed ID: 17461423
[TBL] [Abstract][Full Text] [Related]
34. Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line.
Venereo-Sanchez A; Simoneau M; Lanthier S; Chahal P; Bourget L; Ansorge S; Gilbert R; Henry O; Kamen A
Vaccine; 2017 Jul; 35(33):4220-4228. PubMed ID: 28648546
[TBL] [Abstract][Full Text] [Related]
35. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.
Coronel J; Behrendt I; Bürgin T; Anderlei T; Sandig V; Reichl U; Genzel Y
Vaccine; 2019 Nov; 37(47):7011-7018. PubMed ID: 31266669
[TBL] [Abstract][Full Text] [Related]
36. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture.
Broussau S; Jabbour N; Lachapelle G; Durocher Y; Tom R; Transfiguracion J; Gilbert R; Massie B
Mol Ther; 2008 Mar; 16(3):500-7. PubMed ID: 18180776
[TBL] [Abstract][Full Text] [Related]
37. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
[TBL] [Abstract][Full Text] [Related]
38. Production of lentiviral vectors in suspension cells using low proportion of supercoiled circular plasmid DNA.
Lu XA; He T; Han Z; Ding Y; Zhao L; Liu G; De Smet F; Huang X; Chen D; Qi F; Zhao X
Cytotechnology; 2020 Oct; 72(6):897-905. PubMed ID: 33123933
[TBL] [Abstract][Full Text] [Related]
39. Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production.
Nikolay A; Léon A; Schwamborn K; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2018 Oct; 102(20):8725-8737. PubMed ID: 30091043
[TBL] [Abstract][Full Text] [Related]
40. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration.
Cooper AR; Patel S; Senadheera S; Plath K; Kohn DB; Hollis RP
J Virol Methods; 2011 Oct; 177(1):1-9. PubMed ID: 21784103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
